That assumes we know all the information and can in hindsight...

That assumes we know all the information and can in hindsight determine what could and should have been done. The jury is out on Managment team especially when you consider 3 of those listed 1 year ago are no longer listed on the website. It is not typical for the President of the company being the FDA interface especially when they have VP Regulatory with over 30 years dermatology experience and CMO also with considerable Dermatology as per their March 2020 slide deck. Vince certainly helped to provide legitimacy (based on his involvement with the Anacor sale )to raise money last year but his time at Dermavant Sciences was not as prolific and currently we don’t yet know which one we got. MC took an odd departure right when things started to get interesting and returned when smoke began to clear even now isn’t sharing in the golden ticket options we are being asked to approve. Let’s see what the outcome for the FDA meeting is before we give them a significant portion of the remaining funds. https://www.sec.gov/Archives/edgar/data/1753483/000095012318012452/filename7.htm